Integrated

Today we shared initial results from our Phase I study of ELE-101 and the exciting news that the first patients have been dosed in our Phase IIa study of ELE-101 for Major Depressive Disorder (MDD), commonly known as depression. ELE-101 is our synthetic intravenous formulation of psilocin benzoate and has been specifically designed to provide consistent and controllable drug delivery in patients with neuropsychiatric conditions, with the potential to produce a more rapid onset, significantly shorter treatment duration and reduced inter-subject variability compared to oral formulations of psilocybin. Dr Rob Conley, Chief Scientific and Medical Officer at Beckley Psytech, said: “Dosing the first patients in our Phase II study marks an important milestone in our clinical development programme of ELE-101 as we investigate its potential as an effective and rapid-acting intervention for depression. This study builds on the foundational work from our Phase I study in healthy volunteers and we are proud to be leading the way in exploring how short-duration psychedelics like ELE-101 could address the huge unmet need faced by the millions of people living with depression around the world and the healthcare systems who support them.” Read more here: https://lnkd.in/eGEQdi8h

We have launched a new Impact Report and Peer Support Pilot Program in collaboration with the Psychedelic Participant Advocacy Network - PsyPAN. The report shares novel insights from psychedelic clinical trial participants and maps their experiences throughout a clinical trial, from recruitment and pre-treatment, to dosing and integration. The report aims to amplify the voice of the participant and highlights potential improvements for future participant experiences. In particular, the report spotlights the need for post-trial support. In light of this finding, we are proud to announce that we have given PsyPAN an unrestricted grant to initiate a 12-month peer support pilot program aimed at supporting trial participants in the UK. Caroline Lilley, Chief Impact Advisor at Beckley Psytech, said: “The launch of this report and PsyPAN’s peer support program is the culmination of an extensive, years-long collaboration between Beckley Psytech and PsyPAN. At Beckley Psytech, we are committed to listening to, and learning from, patient and participant experiences and I want to take this opportunity to thank the patient experts for their honesty and courage. We encourage all interested stakeholders to read the report and we hope to see further partnership between industry and patient groups in the future.” In recognition of the Patient Council project, and the collaboration between Beckley Psytech and PsyPAN, Beckley Psytech also announced today that it had received the Silver Standard in OVID Health's 2024 #PatientPartnershipIndex. The Index is an annual celebration of high-quality, meaningful partnerships between patient groups and pharmaceutical companies, and this is the second consecutive year that Beckley Psytech has been recognised for its patient-focused work. To read the report and learn more about the peer support program, please click here: https://lnkd.in/eYMam-AW

The first participant has been dosed in a new research study exploring the effects of BPL-003 on the human brain. The study, which is being conducted at Imperial College London will investigate the neurophysiological effects of BPL-003 - Beckley Psytech’s novel synthetic intranasal formulation of the psychedelic 5-MeO-DMT  - in the brains of healthy volunteers in order to better understand how 5-MeO-DMT elicits its profound consciousness-altering effects. Commenting on the study, Dr Rob Conley, Chief Scientific and Medical Officer at Beckley Psytech, said: "We are very proud to be supporting world-leading researchers at Imperial College London to learn more about how our lead compound, BPL-003, works in the human brain. Literature suggests an association between intensity of psychedelic experiences and positive treatment effects, so we are keen to explore further and hopefully uncover new insights that we can use to inform our ongoing clinical studies of BPL-003 for Treatment Resistant Depression and Alcohol Use Disorder.” Read more here: https://lnkd.in/eC5Suisu

It's official! Of the 1400 medtech companies that applied, BrainSpace has been selected as a MedTech Innovator 2024 Accelerator company! Looking forward to the value, visibility and community we will get from participating in this program.

Headed back to DC on Monday for MedTech Innovator where we've been selected to present as part of the 2024 Road Show.

We announced positive initial findings from our Phase IIa study of BPL-003 for Treatment Resistant Depression (TRD) today. A single dose of BPL-003 was shown to deliver a rapid and durable antidepressant response in patients with TRD up to 85 days post-dose. This, combined with the short treatment time of BPL-003, demonstrates the potential for BPL-003 to deliver a more accessible treatment opportunity for people in need with a reduced resource burden on healthcare systems. Commenting on the results, Cosmo Feilding Mellen, Chief Executive Officer at Beckley Psytech, said: "We are delighted to see that a single dose of BPL-003 delivered a rapid and durable antidepressant response in patients with Treatment Resistant Depression. Our single dose treatment model enables a short treatment duration which positions BPL-003 as an exciting and scalable treatment opportunity. Less than 15% of patients with Treatment Resistant Depression achieve long-term remission with the current standard of care, and we look forward to further validating the potential of BPL-003 as a treatment option with our ongoing Phase IIb study and subsequent clinical development program.” Read more about the findings here: https://lnkd.in/evJ-4hUf

Very proud to share that the incredible efforts of the Cybin Inc team have resulted in Breakthrough Therapy designation for CYB003 in MDD with truly remarkable remission rate of 75% at 4 months after dosing. https://lnkd.in/gQ9VK9mh

BrainSpace is back at #lsiusa24 next week. Looking forward to our CEO Caitlin Morse sharing our company progress and introducing our first device that manages intracranial pressure and CSF drainage to protect the brain and help it heal after stroke, TBI, and surgery.

We recently published preclinical data in Frontiers in Neuroscience demonstrating that TSND-201 (methylone) drives neuroplasticity in brain areas associated with #PTSD and #MDD. The study compared TSND-201 with MDMA, revealing unique pharmacological effects. Notably, TSND-201 demonstrated rapid induction of neurotrophic factors, fostering neuroplastic changes essential for fast-acting therapeutics. “These data support the growing body of evidence for TSND-201 as a potential best-in-class medication for various CNS disorders,” said Transcend Therapeutics Co-Founder and CEO Blake Mandell. "This enhances our understanding of the recently presented clinical data from an open-label Phase 2 clinical trial with rapid, robust, and durable therapeutic effects in patients with severe PTSD.”

Thoroughly enjoyed reading this article. Food is Medicine" (FIM) has roots traced back to ancient times. It now has resurgence in modern times due to the increasing recognition of the profound impact of diet on health. This article discusses how factors like economic incentives, industrialization, and cultural changes have led to a detachment between food and health, but recent trends such as public healthcare reforms and a greater understanding of social determinants of health are driving a renewed interest in FIM. #foodasmedicine #foodismedicine